VolitionRx Limited (VNRX) Quick Liquidity

This GURU.Markets price chart illustrating value trends for VolitionRx Limited (VNRX) shows the metric at 0.31. VolitionRx Limited (VNRX) relies on the Nu.Q platform, which identifies pathologies via nucleosomes, and possesses significant pricing power. The business is actively securing agreements with medical networks and veterinary clinics to launch tests; however, integration into government protocols and large-scale accuracy verification remain the primary obstacles, which are protected by patents.

For VolitionRx Limited (VNRX), whose model relies on external financing due to the lack of stable sales of blood analysis systems, the ability to cover obligations without liquidating inventory is critical. This metric aggregates cash and accounts receivable, excluding illiquid assets to assess real-time solvency. A quarterly analysis of the quick ratio determines how resilient the company is to cash flow gaps in an environment of weak operating cash flow.